Xenitra, ASX: XEN (formerly AuMake International): A Transformed Cross-Border Platform with a 290% Valuation Upside Potential
Xenitra (ASX: XEN) has transformed from a tourism-dependent retailer into a diversified cross-border platform connecting Australian and New Zealand health and consumer brands with Greater China. Revenue has grown roughly 15-fold from A$2.7m in FY23 to A$39.8m in FY25, while the company remains valued at only ~0.3x FY25 sales. With growth across nutritionals, OTC medicines and its OPAL platform, supported by major partnerships and favourable Chinese market tailwinds, Xenitra appears positioned for significant margin and earnings growth. A DCF valuation of A$0.0096–A$0.0137 per share implies substantial upside from the current A$0.003 share price.
.webp&w=828&q=75)
Locksley Resources (ASX: LKY): Mojave Exploration Halt Hits Sentiment as Sellers Retake Control
Locksley Resources faces investor pressure after pausing Mojave exploration activities. The company is reassessing project spending, focusing on preserving assets, and reviewing future opportunities across its critical minerals portfolio.
Life360 INC. (ASX:360): Stronger Growth, Expanding Margins and a Bullish Channel Under Pressure
Life360 delivers powerful subscription and advertising growth, expanding margins and accelerating global penetration. Strong MAU momentum, rising Paying Circles, and a breakout technical setup reinforce the company’s position as a high‑growth digital safety leader.
.webp&w=828&q=75)
BlinkLab (ASX: BB1) Gains Momentum: AI Screening Platform Meets a High-Volume BB1 Breakout
BlinkLab (ASX: BB1) is advancing its autism and ADHD assessment technology through clinical studies, FDA validation work, and research partnerships. Recent technical strength reflects growing investor interest, though regulatory and commercial risks remain.
Pro Medicus (ASX: PME): Scaling Global Leadership in Enterprise Imaging and AI‑Driven Diagnostics
Pro Medicus (ASX: PME) delivers record revenue growth, expanding margins, and accelerating AI‑driven innovation, reinforcing its global leadership in enterprise imaging and cloud‑based diagnostics.
.webp&w=828&q=75)
Bannerman Energy (ASX: BMN): Strategic Financing and Etango Execution Momentum
Bannerman Energy (ASX: BMN) advances Etango uranium project with CNNC financing, strong early works execution, and rising uranium prices, positioning as a leveraged mid-cap growth play in a buoyant nuclear fuel market.